It has been suggested that the epidermal growth factor receptor (EGFR) is a receptor for vaccinia virus Specific cell surface receptors are required for efficient entry of viruses into cells, and the presence of such receptors is a major factor in virus tropism. Vaccinia virus encodes a protein termed virus growth factor (VGF) with structural and functional homology to epidermal growth factor (EGF) and transforming growth factor alpha (1, 13, 17, 18) . On the basis of the hypothesis that such a virally encoded protein could be incorporated into the virus envelope and target the virus to the EGF receptor (EGFR), it was suggested that the EGFR could be a receptor for vaccinia virus (7). Support for such a role was obtained from blocking studies using purified EGF, a panel of synthetic peptides with homology to EGF, and monoclonal anti-EGFR antibodies that competitively inhibit binding of EGF to its receptor (7, 14) . These reagents specifically reduced vaccinia virus plaque formation. Because inhibition was maximally 60%, the existence of a second vaccinia virus receptor was postulated (7).
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The EGFR seems to be an attractive candidate as a receptor for vaccinia virus, since it could explain (i) the typical clinical manifestations as an expression of the prominent epithelial cell tropism by members of the poxvirus family and (ii) the broad host cell range in tissue cultures, as the EGFR is ubiquitously expressed on cells other than lymphoid cells, which are mostly resistant to vaccinia virus infection (11) .
Although not addressing this issue specifically, other reports have questioned the requirement of the EGFR for efficient infection with vaccinia virus (3, 4 (Fig. 2) suggested for other viruses (8, 9) . Virus in 0.25 ml of DMEM was added to 2.2 and HER 2.2 cell monolayers, and plates were incubated at 37°C. After the periods indicated, wells were washed twice with DMEM and fresh medium was added. For both cell types, the number of plaques increased with time at the same rate (Fig. 3) , showing that there is no difference between 2.2 and HER 2.2 cells in the kinetics of irreversible virus adsorption. Similarly, virus adsorption at room temperature was slower but occurred at the same rate for both cell lines (data not shown). Thus, these results exclude an accessory role of the EGFR in vaccinia virus binding to cells. Penetration of virus. After adsorption, the vaccinia virus envelope fuses with the cell membrane and the virus core is released into the cytoplasm. Cell structures other than the virus receptor can be involved in virus penetration (19) . To analyze such a role for the EGFR, penetration studies were performed by using resistance to antiserum after adsorption to cells as an indicator (15) . Although not directly measuring virus penetration, such an assay may be biologically more relevant, as virus neutralization can still occur after adsorption to cells but then diminishes with time. Since cell monolayers detached when kept at 4°C, virus adsorption to 2.2 and HER 2.2 cells was done at room temperature. After 5 h, wells were washed twice with DMEM and fresh DMEM was added. At the times indicated before or after transfer of plates to 37°C, a rabbit antiserum to vaccinia virus, diluted in DMEM-1% bovine serum albumin, was added to wells. The final antiserum dilution was 1/150. Two hours after the last time point, 1 ml of DMEM with 3% fetal calf serum was added per well and plaques were visualized 2 days later. These penetration studies (i) show that after 5 h of adsorption at room temperature, the percentage of virus resistant to neutralization is the same for both cell lines (Fig. 4) The conclusions drawn from our results contradict those obtained from blocking studies (7, 14) . Our own experiments, including some blocking studies (data not shown), suggest that a plaque assay may not always be a reliable test for analysis of virus binding to its receptor. The readout of such a test depends on several steps of the infectious cycle of a virus, and there can be variation of plaque formation depending on other critical experimental conditions. For example, we found that vaccinia virus plaque formation, especially on L929 cells and A431 cells, previously used for receptor studies (7, 14) , was dependent on cell density and probably other factors (data not shown). Consideration should also be given to the fact that manipulation of biologically active proteins, such as receptors for growth hormones, may have secondary effects on cells and plaque formation, respectively. In addition, in plaque assays, virus receptor occupation is far from saturating, even at a high virus particle to infectious unit ratio, which is 1:100 for vaccinia virus but can be up to 1:1,000 for some animal viruses (5 
